Skip to content

This site is intended for healthcare professionals in the UK only. Prescribing information and Adverse Event (AE) reporting details can be found in the footer.

  • Why Zegluxen®
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • Patient eligibility
  • Cost savings
  • How to Administer
    • Dose Titration
    • Storage and shelf life
    • Method of administration
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs
  • Why Zegluxen®
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • Patient eligibility
  • Cost savings
  • How to Administer
    • Dose Titration
    • Storage and shelf life
    • Method of administration
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs

How to Administer Dose Titration

As with all GLP-1 receptor agonists, doses need to be administered incrementally and titrated upwards in a step-wise manner, to optimise gastrointestinal tolerability

Two Zegluxen packs side-by-side

As with all GLP-1 receptor agonists, doses need to be administered incrementally and titrated upwards in a step-wise manner, to optimise gastrointestinal tolerability

To facilitate gastro-intestinal tolerability of this therapy:1

  • Starting dose: 6mg liraglutide should be administered once daily
  • After at least 1 week on 0.6 mg once daily (week 2 onwards): the dose should be increased to 1.2 mg liraglutide
  • After at least 1 week on 1.2 mg once daily (week 3 onwards): depending on clinical response some patients may benefit from an increase to 1.8mg, although daily doses of 1.8mg are not recommended

Combinations and monitoring:

  • When Liraglutide is added to a Sulfonylurea or insulin a dose reduction should be considered to reduce hypoglycaemia risk.
  • Combination therapy with sulfonylurea is only valid for adult patients.
  • Self-monitoring of blood glucose is not needed in order to adjust the dose of liraglutide, but is needed to adjust the dose of sulfonylurea and insulin, particularly when liraglutide therapy is started and insulin is reduced.
  • A stepwise approach to insulin dose reduction is recommended
Man in wheelchair smiling at camera
  1. Zegluxen® (liraglutide) Summary of Product Characteristics.

000697557 | November 2024

Prescribing information can be found here

  • Navigation
    • Terms of Use
    • HCP Privacy
    • Cookies Policy
    • GDPR

MORE ABOUT US

linkedin

Reporting of side effects

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Zentiva Pharma UK Ltd via our online form (https://www.zentiva.co.uk/contact/mi-form), by email (UKMedInfo@zentiva.com) or by telephone (0800 090 2408).

Copyright Zentiva Group, a.s. © 2026

I confirm I am a UK Healthcare Professional (HCP)

This page is dedicated to UK HCPs only. If you are not a UK HCP, you will be directed to the gateway page after clicking on No.

No, I am not Yes, I am